CelLBxHealth plc Stock
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
London S.E.
19:35:05 11/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.100 GBX | 0.00% |
|
-4.35% | - |
| Market Cap | 12.5M 16.91M 14.57M 13.79M 23.45M 1.61B 23.59M 164M 63M 821M 63.45M 62.1M 2.6B | P/E 2026 * |
-0.47x | P/E 2027 * | -12.2x |
|---|---|---|---|---|---|
| Enterprise Value | 10.9M 14.74M 12.71M 12.03M 20.45M 1.41B 20.57M 143M 54.94M 716M 55.33M 54.15M 2.26B | EV / Sales 2026 * |
0.5x | EV / Sales 2027 * | 0.37x |
| Free-Float |
95.3% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| CLBX | Delayed | |
Deutsche Boerse AG
| DWV | Delayed |
Last Transcript : CelLBxHealth plc
| 16/10/25 | Angle names Peter Collins as interim CEO | AN |
| 28/05/25 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 23/01/25 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 14/09/23 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 24/01/22 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| 1 week | -4.35% | ||
| Current month | -12.00% | ||
| 1 month | -18.52% | ||
| 3 months | -40.54% | ||
| 6 months | +15.79% |
| 1 week | 1 |  | 1.2 |
| 1 month | 1 | | 1.4 |
| Current year | 0.85 | | 2.8 |
| 1 year | 0.85 | | 4.19 |
| 3 years | 0.85 | | 37.4 |
| 5 years | 0.85 | | 163.75 |
| 10 years | 0.85 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 01/01/1999 |
| Chief Tech/Sci/R&D Officer | - | 01/01/2025 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 05/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 22/05/2023 |
Klaas de Boer
BRD | Director/Board Member | 61 | 12/01/2026 |
| Director/Board Member | 61 | 12/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/12/25 | Buy | Chief Executive Officer | 5,000,000 | 1.5497% | ||
| 19/12/25 | Buy | Chief Financial Officer | 2,500,000 | 0.7749% | ||
| 19/12/25 | Buy | Chairman | 5,000,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -4.35% | -72.64% | -93.04% | 16.91M | |
| +0.87% | -4.86% | +16.71% | -33.27% | 16.65B | |
| -1.77% | +7.05% | -31.49% | +58.12% | 1.78B | |
| +0.08% | -3.83% | -28.36% | +19.34% | 894M | |
| -3.05% | -15.43% | -57.37% | -84.22% | 833M | |
| -0.05% | -0.32% | +68.43% | -3.30% | 778M | |
| -2.56% | -5.08% | -37.23% | -49.60% | 654M | |
| -5.26% | -9.30% | -44.97% | -48.89% | 591M | |
| +3.41% | -15.78% | -44.42% | -39.91% | 436M | |
| +1.82% | -5.18% | +67.02% | +48.52% | 386M | |
| Average | -0.65% | -5.92% | -16.43% | -22.62% | 2.3B | |
| Weighted average by Cap. | +0.27% | -4.95% | +6.80% | -24.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 21.65M 29.28M 25.24M 23.88M 40.62M 2.8B 40.85M 284M 109M 1.42B 110M 108M 4.5B | 37.75M 51.06M 44.01M 41.65M 70.83M 4.88B 71.22M 495M 190M 2.48B 192M 188M 7.84B |
| Net income | -8.55M -11.57M -9.97M -9.43M -16.04M -1.1B -16.13M -112M -43.09M -562M -43.4M -42.47M -1.78B | -1.85M -2.5M -2.16M -2.04M -3.47M -239M -3.49M -24.27M -9.32M -122M -9.39M -9.19M -384M |
| Net Debt | -1.6M -2.16M -1.87M -1.77M -3M -207M -3.02M -20.99M -8.06M -105M -8.12M -7.95M -332M | 1.4M 1.89M 1.63M 1.54M 2.63M 181M 2.64M 18.37M 7.06M 91.96M 7.11M 6.95M 291M |
Employees
114
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | GBX 1.100 | 0.00% | 156,495 |
| 10/09/26 | GBX 1.100 | 0.00% | 219,548 |
| 09/09/26 | GBX 1.100 | 0.00% | 938,803 |
| 08/09/26 | GBX 1.100 | 0.00% | 1,079,281 |
| 07/09/26 | GBX 1.100 | 0.00% | 1,052,981 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0110GBP
Average target price
0.0400GBP
Spread / Average Target
+263.64%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
